10-Q: GRAIL, Inc. Reports Third Quarter 2024 Results Following Spin-Off from Illumina

GRAIL, Inc. reports a net loss of $125.7 million for the third quarter of 2024, following its spin-off from Illumina and a restructuring plan.

Summary

• GRAIL, Inc. reported a net loss of $125.7 million for the three months ended September 30, 2024, and a net loss of $1.9 billion for the nine months ended September 30, 2024.
• The company's screening revenue increased to $25.2 million in Q3 2024, up from $16.6 million in Q3 2023.
• Development services revenue decreased to $3.3 million in Q3 2024, down from $4.0 million in Q3 2023.
• The company incurred restructuring charges of $19.0 million in Q3 2024.
• GRAIL received $932.3 million in disposal funding from Illumina in connection with the spin-off.
• The company's cash and cash equivalents totaled $853.6 million as of September 30, 2024.
• The company believes its existing cash and cash equivalents will be sufficient to meet its working capital and capital expenditure needs for at least the next 12 months.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While revenue is growing and cost-cutting measures are being implemented, the significant net losses and reliance on sole suppliers raise concerns. The restructuring plan and cash runway extension are positive, but the company faces significant challenges in achieving profitability and obtaining regulatory approvals.

Positives

• Screening revenue increased by 52% year-over-year in Q3 2024, driven by a 57% increase in Galleri sales volume.
• The company's restructuring plan is expected to result in approximately $120 million in annual cost savings.
• GRAIL received $932.3 million in disposal funding from Illumina in connection with the spin-off.
• The company believes its existing cash and cash equivalents will be sufficient to meet its working capital and capital expenditure needs for at least the next 12 months.

Negatives

• GRAIL reported a net loss of $125.7 million for Q3 2024 and a net loss of $1.9 billion for the nine months ended September 30, 2024.
• Development services revenue decreased by 18% year-over-year in Q3 2024.
• The company incurred restructuring charges of $19.0 million in Q3 2024.
• The company recognized a goodwill impairment of $888.9 million and an IPR&D impairment of $532 million in the nine months ended September 30, 2024.

Risks

• The company operates in a rapidly evolving field and has a limited operating history.
• GRAIL has incurred significant net losses since inception and anticipates continuing to incur net losses for the coming years.
• The company's products may not perform as expected, and clinical study results may not support product launches or regulatory approvals.
• The clinical study process is lengthy and expensive with uncertain outcomes.
• A substantial majority of the company's revenue is generated from sales of Galleri, making it highly dependent on this product.
• If the company's products do not receive adequate coverage and reimbursement, its commercial success will be limited.
• The company's commercial products may fail to achieve the degree of market acceptance necessary for commercial success.
• The regulatory clearance, approval, or certification processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and unpredictable.
• The company may not be able to generate sufficient revenue to offset its ongoing operating expenses and achieve and maintain profitability.
• The company relies on sole suppliers for key components, including Illumina for next-generation sequencers and associated reagents, Madison Industries for blood collection tubes, and Twist Bioscience Corporation for DNA panels.
• The company's operations and business are materially dependent on various third parties, any of which could experience disruption, failure, or interruption.
• If the company is unable to scale its operations to support demand for its products, its business could suffer.
• If the company is not successful in attracting, motivating, and retaining highly qualified personnel, it may not be able to successfully implement its business strategy.
• The company's quarterly results of operations may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause its stock price to fluctuate or decline.
• If the company fails to obtain additional financing, it may be unable to expand its commercialization efforts or to develop and commercialize additional products.
• If the company's products result in direct or indirect participant or patient harm or injury, it could be subject to significant reputational and liability risks.
• The company could have an indemnification obligation to Illumina if the Distribution were determined not to qualify for non-recognition treatment for U.S. federal tax purposes.
• The company has agreed to numerous restrictions to preserve the non-recognition treatment of the Spin-Off, which may reduce its strategic and operating flexibility.
• An active trading market for the company's common stock may not be sustained and its stock price may fluctuate significantly.
• Securities analysts may not publish research or reports about the company's business or may publish negative evaluations of its stock.
• Raising additional capital may cause dilution to the company's existing stockholders, restrict its operations, or require it to relinquish rights to its technologies or its products.
• The company is an emerging growth company and the information it provides shareholders may be different from information provided by other public companies.
• Substantial sales of the company's common stock may occur in connection with the Spin-Off, including the disposition by Illumina of the shares of the company's common stock that it retains after the Spin-Off.

Future Outlook

The company plans to complete a PMA submission with the FDA in the first half of 2026 and expects the restructuring plan to extend its anticipated cash runway from the second half of 2026 into 2028.

Management Comments

• The company believes that its existing cash and cash equivalents will be sufficient to meet its working capital and capital expenditure needs for at least the next 12 months.
• The company expects the headcount reductions to enable future cost savings of approximately $120 million on an annual basis, with approximately $27 million in savings, net of severance and benefits, in 2024.

Industry Context

The multi-cancer early detection market is relatively new and evolving, with several companies developing competing tests and technologies. GRAIL is working to establish MCED as a standard of care for cancer screening.

Comparison to Industry Standards

• The company's revenue growth in screening is strong, but the company is still in the early stages of commercialization and is not yet profitable.
• The company's reliance on sole suppliers is a risk, as is the potential for competition from other companies in the MCED space.
• The company's restructuring plan is a positive step towards cost control, but the company will need to continue to manage its expenses carefully.
• The company's cash position is strong, but it will need to raise additional capital in the future to fund its operations.

Legal Proceedings

• The company is involved in various lawsuits and claims arising in the ordinary course of business, including actions with respect to employment matters.
• The company is involved in securities class action litigation related to the acquisition of GRAIL by Illumina.
• The company has an indemnification obligation for certain current and former directors and officers involved in the securities class action litigation.

Related Party Transactions

• The company has entered into an amendment to its Supply and Commercialization Agreement with Illumina, which includes a high single-digit royalty payment to Illumina in perpetuity on net sales generated by its products or revenues otherwise generated or received by the company, subject to certain exceptions, in the field of oncology.
• The company has related party transactions with Twist Bioscience, a supplier to the company, due to a board member also serving on the board of Twist Bioscience.

Stakeholder Impact

• Shareholders may be concerned about the company's significant net losses and the potential for dilution from future capital raises.
• Employees may be affected by the company's restructuring plan, which includes a reduction in headcount.
• Customers may be concerned about the company's reliance on sole suppliers and the potential for disruptions in service.
• Suppliers may be affected by the company's restructuring plan and its efforts to reduce costs.
• Creditors may be concerned about the company's ability to repay its debts if it does not achieve profitability.

Next Steps

• The company plans to complete a PMA submission with the FDA in the first half of 2026.
• The company will continue to work with the FDA regarding the data needed to support its PMA submission.
• The company will continue to invest in its biopharmaceutical partnerships and work with its partners to leverage its proprietary methylation technology in precision oncology applications.
• The company will continue to evaluate international expansion opportunities and expects to expand into additional select geographies over time, including through distributors.

Key Dates

Keywords

GRAIL, Galleri, multi-cancer early detection, MCED, cancer screening, Illumina, spin-off, restructuring, FDA, PMA, clinical trials, reimbursement, laboratory developed test, LDT, methylation, genomics, oncology